CompletedNot Applicable

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

France342 participantsStarted 2021-01-07

Plain-language summary

This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III - IV) epithelial ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer who have completed first line platinum-based chemotherapy, in PR/CR and treated with at least one dose of olaparib in first line maintenance setting * Patients aged ≥18 years old * Ability and/or willingness to provide a signed informed consent form (where required) Exclusion Criteria: * Withdrawal of informed consent (where consent required) * Concurrent participation in any clinical study with an investigational product at the time of olaparib initiation

What they're measuring

Progression

Timeframe: 36 months

Trial details

NCT IDNCT04532645

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-09-27

View on ClinicalTrials.gov More Ovary Cancer trials